This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
GS 0573
Accession Number
DB08843
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
External IDs
GS 0573 / GS-0573
Categories
UNII
5EX1YUR4DH
CAS number
113852-41-8
Weight
Average: 288.204
Monoisotopic: 288.073589921
Chemical Formula
C8H13N6O4P
InChI Key
XHXFQGAZAVKMFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H13N6O4P/c9-6-5-7(13-8(10)12-6)14(3-11-5)1-2-18-4-19(15,16)17/h3H,1-2,4H2,(H2,15,16,17)(H4,9,10,12,13)
IUPAC Name
{[2-(2,6-diamino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid
SMILES
NC1=NC(N)=C2N=CN(CCOCP(O)(O)=O)C2=N1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of GS 0573.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of GS 0573.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with GS 0573.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when GS 0573 is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when GS 0573 is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when GS 0573 is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with GS 0573.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of GS 0573.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with GS 0573.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when GS 0573 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when GS 0573 is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of GS 0573.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of GS 0573.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with GS 0573.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of GS 0573.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of GS 0573.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of GS 0573.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of GS 0573.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with GS 0573.Approved, Investigational
FingolimodGS 0573 may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when GS 0573 is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when GS 0573 is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of GS 0573.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when GS 0573 is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when GS 0573 is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when GS 0573 is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when GS 0573 is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when GS 0573 is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when GS 0573 is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of GS 0573.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when GS 0573 is combined with Leflunomide.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of GS 0573.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when GS 0573 is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of GS 0573.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of GS 0573.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of GS 0573.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with GS 0573.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of GS 0573.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with GS 0573.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of GS 0573.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when GS 0573 is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with GS 0573.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when GS 0573 is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of GS 0573.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when GS 0573 is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when GS 0573 is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when GS 0573 is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when GS 0573 is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with GS 0573.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when GS 0573 is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of GS 0573.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when GS 0573 is combined with Tecemotide.Investigational
TG4010The risk or severity of adverse effects can be increased when GS 0573 is combined with TG4010.Investigational
TofacitinibGS 0573 may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of GS 0573.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when GS 0573 is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when GS 0573 is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
58513
ChEMBL
CHEMBL61733

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.94 mg/mLALOGPS
logP-2ALOGPS
logP-4.7ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)1.36ChemAxon
pKa (Strongest Basic)6.02ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area162.4 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity67.76 m3·mol-1ChemAxon
Polarizability25.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
6-aminopurines
Alternative Parents
Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Organic phosphonic acids / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds
show 2 more
Substituents
6-aminopurine / Aminopyrimidine / N-substituted imidazole / Pyrimidine / Imidolactam / Azole / Imidazole / Organophosphonic acid / Organophosphonic acid derivative / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 Sep;56(3):570-80. [PubMed:10462545]

Drug created on February 27, 2013 14:56 / Updated on March 02, 2018 03:42